For research use only. Not for therapeutic Use.
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo [1] [2].
Enavatuzumab (0.1-1000 ng/mL; 4 hours) induces effector cell activation and tumor cell killing in vitro[1].
Enavatuzumab (10 μg/mL; for 24 hours) results in significantly increased migration of immune effector cells toward the tumor cells in SN12C and A375 cells[1].
Enavatuzumab (10 mg/kg; IP; three times per week; 7 doses) shows diverse antitumor activities on different xenograft tumors[1].
| Catalog Number | I042231 |
| CAS Number | 1062149-33-0 |
| Purity | ≥95% |
| Reference | [1]. Shiming Ye, et al. Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells. J Immunol Res. 2017;2017:5737159. [2]. Ludmilla de Plater, et al. Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts. PLoS One. 2014 Nov 6;9(11):e104227. |
